Physician profile
Karen Moore
NPI 1881469203
$904.46
in general payments reported to CMS, 2019-2025
13 companies · $589 in 2025
The $589 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $316 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.70 | 2024-2025 | |
| Pfizer INC. | $187.38 | 2024-2025 | |
| Novo Nordisk INC | $91.18 | 2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $87.13 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $55.20 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $55.17 | 2024-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $43.77 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $36.73 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $25.86 | 2025 | Spravato |
| Harmony Biosciences LLC | $19.81 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.10 | 2025 | Caplyta |
| Lilly USA, LLC | $14.05 | 2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.38 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.